Our mission is to discover, develop, and commercialize medicines that improve the lives of patients by combining the potential of high-value GPCR drug targets with the power of state-of-the-art small molecule drug discovery technologies. Septerna’s Native Complex Platform™ is the engine that will make this happen, moving ideas for disease-modifying therapies from possibility to reality.

Septerna has assembled a team that thrives on innovation, combining pioneering GPCR scientists with experienced drug hunters. Our founders have made seminal discoveries that reveal the inner workings of GPCRs and how they control physiology. Our scientists have built upon these unique insights to develop our industrial-scale Native Complex Platform™.

We are focusing the Native Complex Platform™ on tackling previously difficult-to-drug GPCR targets, and our small molecule drug discovery efforts have rapidly advanced, resulting in a pipeline of innovative programs. With an unprecedented level of productivity, we are setting the stage for a new future for GPCR-targeted medicines.

                    Hypoparathyroidism is a rare endocrine disease characterized by low levels of parathyroid hormone (PTH) caused by the loss of the parathyroid glands, frequently after neck                      surgery. The disease affects approximately 70,000 patients in the United States and 140,000 patients in Europe. The loss of PTH, which is a master regulator of calcium                                      homeostasis, leads to an array of challenging symptoms and life-threatening complications for hypoparathyroidism patients including muscle cramps, fatigue, cognitive                                dysfunction and brain fog, cardiac arrhythmias, seizures, kidney calcification and renal failure. Many patients experience persistent symptoms that negatively impact                                      quality of life.

                    Oral Small Molecule PTH1R Agonists for Hypoparathyroidism

                    Our strategy to address hypoparathyroidism is to develop an oral small molecule that functionally replaces PTH by activating PTH1R in bones and the kidneys to restore                                normal calcium control and provides a convenient oral option for all hypoparathyroidism patients.   

Septerna pipeline Oral PTHR1 receptor - We are working on oral replacements for injectable GPCR peptide drugs